Semaglutide 1.7mg Pen Injection is a prescription once-weekly GLP-1 receptor agonist injection containing semaglutide 1.7mg for subcutaneous administration. The 1.7mg strength is an established semaglutide injection dose and is specifically available in the Wegovy® semaglutide injection dosage range. Current U.S. prescribing information lists 1.7mg among the available prefilled pen strengths.
Semaglutide works through GLP-1 receptors involved in appetite regulation, food intake and glucose metabolism. Depending on the specific product and regulatory authorization, semaglutide may be prescribed for chronic weight management and other approved indications.
Semaglutide 1.7mg Pen Injection contains 1.7mg of semaglutide in a prefilled injection pen intended for subcutaneous administration.
The 1.7mg strength is an established strength of Wegovy® injection. Current FDA prescribing information lists prefilled single-dose pens delivering 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg of semaglutide.
For appropriate patients, semaglutide injection is used alongside a reduced-calorie diet and increased physical activity for approved weight-management indications. Current U.S. labeling also includes cardiovascular-risk reduction in certain adults with established cardiovascular disease and overweight or obesity.
Semaglutide is a GLP-1 receptor agonist that activates GLP-1 receptors involved in appetite, food intake and glucose regulation.
Its effects include:
Depending on the specific product and approved indication, semaglutide injection may be prescribed for:
Current U.S. Wegovy labeling includes chronic weight management and reduction of major cardiovascular events in specified eligible patients.
Semaglutide injection is generally titrated gradually rather than started at 1.7mg.
For Wegovy injection, treatment is initiated at 0.25mg once weekly, followed by dose escalation at four-week intervals. The 1.7mg dose is one of the established higher-dose strengths in the regimen. Current labeling identifies 2.4mg once weekly as the usual recommended maintenance dose, with maintenance dosing determined according to the approved indication.
The appropriate dose should be determined by a qualified healthcare professional based on the specific product, indication, tolerability and treatment response.
Wegovy® is the branded semaglutide injection associated with the 1.7mg pen strength.
Current U.S. product information describes Wegovy 1.7mg as a prefilled single-dose pen delivering 1.7mg of semaglutide.
A Semaglutide 1.7mg Pen manufactured by another company may contain the same active ingredient and strength, but its manufacturer, formulation, pen device, packaging and regulatory status may differ.
Where legally authorized, commercially relevant search terms include:
Semaglutide 1.7mg → Semaglutide 1.7mg Injection → Generic Semaglutide 1.7mg → Generic Wegovy 1.7mg → Wegovy 1.7mg Alternative
Generic Semaglutide 1.7mg refers to a semaglutide product manufactured and marketed by a company other than the reference-brand manufacturer where such generic or equivalent marketing is legally authorized.
For commercial search intent, relevant keyword relationships include:
Semaglutide 1.7mg Pen Injection is a prescription medicine. Availability, dispensing requirements and legal importation vary by country.
Customers searching for Semaglutide 1.7mg Pen Injection, Semaglutide 1.7mg Injection, Generic Semaglutide 1.7mg, Buy Semaglutide 1.7mg, Semaglutide 1.7mg Price, Generic Wegovy 1.7mg, Wegovy 1.7mg Alternative and related commercial terms can check availability through appropriately licensed pharmacies and pharmaceutical suppliers.
Prescription and import regulations differ across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
Semaglutide 1.7mg Pen Injection is a prescription injectable medicine containing 1.7mg of semaglutide, a GLP-1 receptor agonist administered subcutaneously.
The 1.7mg strength is an established dose in semaglutide injection regimens, particularly for approved chronic weight-management treatment. The exact indication depends on the specific product and country.
Yes. Semaglutide is a GLP-1 receptor agonist.
Established semaglutide injection products such as Wegovy are administered once weekly. The injection should be used exactly according to the prescribing information for the specific product.
No. Established Wegovy injection treatment starts at 0.25mg once weekly, followed by gradual dose escalation. The 1.7mg strength is reached later in the dosing schedule.
Both refer to semaglutide at the 1.7mg strength, but Wegovy® is a specific branded product. A semaglutide product from another manufacturer should only be described as a generic or equivalent product where legally authorized.
No. Although both Ozempic and Wegovy contain semaglutide, they are distinct branded products with different approved indications and dosing information. The 1.7mg injection strength is specifically associated with Wegovy’s semaglutide injection dosage range.
Semaglutide is prescription medicine. Online purchasing should be through an appropriately licensed pharmacy or pharmaceutical supplier and must comply with the laws of the destination country.
Common adverse effects can include nausea, diarrhea, vomiting, constipation and abdominal discomfort. Gastrointestinal adverse reactions can sometimes be significant, particularly during dose escalation.
Current U.S. Wegovy labeling contraindicates use in patients with a personal or family history of medullary thyroid carcinoma (MTC), patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or those with a known serious hypersensitivity to semaglutide or product ingredients.
Storage requirements depend on the specific product and pen formulation. Follow the manufacturer’s current storage instructions and do not use a product that has been improperly stored or frozen.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Semaglutide is a prescription medicine and should only be used under the supervision of a qualified healthcare professional. Indications, dosing, contraindications, warnings, formulation, storage requirements and availability may vary by manufacturer and country. Always refer to the official prescribing information for the specific product.
Last Updated: August 23, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Semaglutide 1.7mg Pen Injection
Reviews
There are no reviews yet